CTRI/2022/07/044193尚未招募3 期
Optimizing chemotherapy in the first line for frail older patients with advanced non-small cell lung cancer.
试验速览
- 阶段
- 3 期
- 状态
- 尚未招募
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Age = 60 years
- •2. Histologically or cytologically confirmed non-small cell lung carcinoma (NSCLC).
- •3. Absence of sensitizing EGFR mutation and absence of EML4-ALK fusion. Patient is not planned for molecular targeted therapy, including EGFR-directed oral tyrosine kinase inhibitor or ALK-directed oral tyrosine kinase inhibitor. Patients with molecularly driven NSCLC who cannot receive molecularly targeted therapy for any reason and who are planned for first-line palliative intent chemotherapy will be eligible for the trial.
- •4. Planned for palliative intent chemotherapy in the first line.
- •5. ECOG PS 0 to 2 (on a 6-point scale ranging from 0 to 5, with higher scores indicating increasing disability; a score of 0 indicates no symptoms, 1 indicates mild symptoms and restricted in physically strenuous activities but ambulatory and able to do light work; and 2 indicates that the patient is ambulatory and capable of all selfcare but unable to do any work, and is up and about over half of the waking hours)
排除标准
- •1. Known severe hypersensitivity to platinum, pemetrexed or any of the excipients of these products or pre-medications.
- •2. Any evidence of severe or uncontrolled systemic disease (e.g. unstable or uncompensated respiratory, cardiac, hepatic or renal disease) as judged by the investigator
- •3. Evidence of any other significant clinical disorder or laboratory finding that makes it undesirable for the patient to participate in the study.
- •4. Inadequate organ function.
研究者
相似试验
进行中（未招募）
不适用
Chemotherapy of first line reinforced for cancers of the colonist and the rectum with hepatic and/or pulmonary metastases potentially résécables: Strong association FOLFIRI and ERBITUX - ERBIFORTcancers of the colonist and the rectumEUCTR2007-000357-54-FRniversityHospitalGrenoble
进行中（未招募）
不适用
Individualised choise of 1.line chemotherapy of metastatic colo-rectal cancer. Can the blood test: TIMP-1 help the doctor to choose the best chemotherapy for the individual patient?Metastatic colon or rectal cancerMedDRA version: 14.1Level: PTClassification code 10027457Term: Metastases to liverSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: PTClassification code 10010035Term: Colorectal cancer stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-005495-42-DKKell Osterlind210
进行中（未招募）
1 期
Induction chemotherapy followed by standard concurrent chemoradiotherapy in cervical cancer with para-aortic lymph node involvement: A phase III, multicenter, parallel-group randomized, controlled trial - ONCOCOL-01MedDRA version: 21.1Level: LLTClassification code: 10008229Term: Cervical cancer Class: 10029104MedDRA version: 21.1Level: LLTClassification code: 10008236Term: Cervical cancer stage IV Class: 10029104MedDRA version: 21.1Level: LLTClassification code: 10008235Term: Cervical cancer stage III Class: 10029104Cervical CancerCTIS2024-513576-18-00Centre Hospitalier Universitaire De Toulouse310
暂停
3 期
Induction chemotherapy followed by standard concurrent chemoradiotherapy in cervical cancer with para-aortic lymph node involvement: A phase III, multicenter, parallel-group randomized, controlled trial - ONCOCOL-01Cervical Cancer2024-513576-18-00Centre Hospitalier Universitaire De Toulouse310
进行中（未招募）
不适用
Induction chemotherapy followed by chemoradiation with cetuximab and cisplatin for inoperable squamous cell carcinoma of the head and neck.Inoperable squamous cell carcinoma of the head and neck.EUCTR2006-003381-33-SIInstitute of Oncology Ljubljana